E. Januszewicz

1.3k total citations
41 papers, 957 citations indexed

About

E. Januszewicz is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, E. Januszewicz has authored 41 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 21 papers in Genetics and 14 papers in Pathology and Forensic Medicine. Recurrent topics in E. Januszewicz's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Acute Myeloid Leukemia Research (10 papers). E. Januszewicz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (13 papers) and Acute Myeloid Leukemia Research (10 papers). E. Januszewicz collaborates with scholars based in Australia, Israel and United States. E. Januszewicz's co-authors include H. Miles Prince, John F. Seymour, Constantine S. Tam, David Westerman, Max Wolf, Dennis Carney, E Aghai, Robert Peter Gale, A. Berrebi and Eli Canaani and has published in prestigious journals such as The Lancet, Blood and Cancer.

In The Last Decade

E. Januszewicz

41 papers receiving 915 citations

Peers

E. Januszewicz
Po Dunn Taiwan
Rachel L. Sargent United States
R H Herzig United States
M. L. Vegna Italy
Francesc Cobo Spain
Hirotaka Takasaki Japan
Delvyn C. Case United States
Christos Kiamouris Greece
Nathalie Cambier France
Hari Menon India
Po Dunn Taiwan
E. Januszewicz
Citations per year, relative to E. Januszewicz E. Januszewicz (= 1×) peers Po Dunn

Countries citing papers authored by E. Januszewicz

Since Specialization
Citations

This map shows the geographic impact of E. Januszewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Januszewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Januszewicz more than expected).

Fields of papers citing papers by E. Januszewicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Januszewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Januszewicz. The network helps show where E. Januszewicz may publish in the future.

Co-authorship network of co-authors of E. Januszewicz

This figure shows the co-authorship network connecting the top 25 collaborators of E. Januszewicz. A scholar is included among the top collaborators of E. Januszewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Januszewicz. E. Januszewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheah, Chan Y., Kirsten Herbert, Glen Kennedy, et al.. (2014). A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer. 111(6). 1072–1079. 89 indexed citations
2.
Cheah, Chan Y., Stephen O. Brennan, Hannah Kennedy, et al.. (2012). Fibrinogen Melbourne. Blood Coagulation & Fibrinolysis. 23(6). 563–565. 9 indexed citations
3.
Peinert, Stefan, Constantine S. Tam, H. Miles Prince, et al.. (2010). Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leukemia & lymphoma. 51(12). 2188–2197. 12 indexed citations
4.
Carney, Dennis, David Westerman, Constantine S. Tam, et al.. (2010). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24(12). 2056–2062. 68 indexed citations
5.
Tam, Constantine S., Max Wolf, H. Miles Prince, et al.. (2006). Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma. Cancer. 106(11). 2412–2420. 75 indexed citations
6.
Polizzotto, Mark N., Constantine S. Tam, Alvin Milner, et al.. (2006). The influence of increasing age on the deliverability and toxicity of fludarabine‐based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer. 107(4). 773–780. 8 indexed citations
7.
Tam, Constantine S., Max Wolf, David Westerman, et al.. (2005). Fludarabine Combination Therapy Is Highly Effective in First-Line and Salvage Treatment of Patients with Waldenström's Macroglobulinemia. Clinical Lymphoma & Myeloma. 6(2). 136–139. 28 indexed citations
8.
Tam, Constantine S., Max Wolf, E. Januszewicz, et al.. (2004). A new model for predicting infectious complications during fludarabine‐based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 101(9). 2042–2049. 22 indexed citations
9.
Seymour, John F., et al.. (2002). Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 43(9). 1783–1788. 51 indexed citations
10.
Prince, H. Miles, Dominic Wall, Danny Rischin, et al.. (2002). CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy. 4(2). 147–155. 7 indexed citations
11.
Campbell, Lynda J., et al.. (2002). BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genetics and Cytogenetics. 139(1). 30–33. 62 indexed citations
12.
Dowling, Anthony, H. Miles Prince, A. Wirth, et al.. (2001). High‐dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience. Internal Medicine Journal. 31(5). 279–289. 6 indexed citations
13.
14.
Campbell, Lynda J., et al.. (1999). Correlation of cytogenetics, BCR‐ABL PCR studies and fluorescence in situ hybridisation (FISH) in adult acute lymphoblastic leukaemia. Australian and New Zealand Journal of Medicine. 29(5). 707–712. 4 indexed citations
15.
Strickland, A. H., et al.. (1999). Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia. Australian and New Zealand Journal of Medicine. 29(4). 556–558. 1 indexed citations
16.
Januszewicz, E. & Frank Firkin. (1988). DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC DISORDERS. IS DIFFERENTIATION‐INDUCTION THERAPY POSSIBLE?. Australian and New Zealand Journal of Medicine. 18(5). 705–711. 3 indexed citations
17.
18.
Januszewicz, E., et al.. (1988). Butyric acid: Inhibition of non-leukemic and chronic myeloid leukemia granulocyte macrophage clonal growth. Medical Oncology and Tumor Pharmacotherapy. 5(4). 259–263. 7 indexed citations
19.
Garson, O. Margaret, et al.. (1987). Hybrid biphenotypic acute leukemia with extreme hypodiploidy. Pathology. 19(2). 197–200. 8 indexed citations
20.
Januszewicz, E., Frank Firkin, C N Chesterman, et al.. (1982). Retrospective Analysis of 158 Cases of Adult Acute Leukaemia: Factors Influencing Prognosis and Treatment Response. Australian and New Zealand Journal of Medicine. 12(3). 238–245. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Po Dunn Breakdown of academic impact, for papers by Rachel L. Sargent Breakdown of academic impact, for papers by R H Herzig Breakdown of academic impact, for papers by M. L. Vegna Breakdown of academic impact, for papers by Francesc Cobo Breakdown of academic impact, for papers by Hirotaka Takasaki Breakdown of academic impact, for papers by Delvyn C. Case Breakdown of academic impact, for papers by Christos Kiamouris Breakdown of academic impact, for papers by Nathalie Cambier Breakdown of academic impact, for papers by Hari Menon
Rankless by CCL
2026